[
1. Rajguru JP, Maya D, Kumar D, Suri P, Bhardwaj S, Patel ND. Update on psoriasis: A review. J Family Med Prim Care. 2020; 9 (1): 20-24.10.4103/jfmpc.jfmpc_689_19
]Search in Google Scholar
[
2. Rønholt K, Iversen L. Old and New Biological Therapies for Psoriasis. Int J Mol Sci. 2017; 18 (11): 2297.10.3390/ijms18112297
]Search in Google Scholar
[
3. Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br J Dermatol. 2021; 184 (1): 14-24.10.1111/bjd.19380
]Search in Google Scholar
[
4. Tampa M, Caruntu C, Mitran M, Mitran C, Sarbu I, Rusu LC, et al. Markers of Oral Lichen Planus Malignant Transformation. Dis Markers. 2018; 2018:1959506.10.1155/2018/1959506
]Search in Google Scholar
[
5. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin- 17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009; 160 (2): 319-24.10.1111/j.1365-2133.2008.08902.x
]Search in Google Scholar
[
6. Gaffen, Sarah L. Structure and signalling in the IL-17 receptor family. Nature reviews. Immunology vol. 9,8 (2009): 556-67.10.1038/nri2586
]Search in Google Scholar
[
7. Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012; 130 (1): 145-54.e9.10.1016/j.jaci.2012.04.024
]Search in Google Scholar
[
8. Brembilla NC, Senra L, Boehncke WH. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front Immunol. 2018; 9:1682.10.3389/fimmu.2018.01682
]Search in Google Scholar
[
9. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386 (9999): 1137-1146.10.1016/S0140-6736(15)61134-5
]Search in Google Scholar
[
10. Spindeldreher S, Maillère B, Correia E, Tenon M, Karle A, Jarvis P, et al. Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab. Dermatol Ther (Heidelb). 2018; 8 (1): 57-68.10.1007/s13555-018-0220-y582532529392570
]Search in Google Scholar
[
11. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013; 168 (2): 402-11.10.1111/bjd.12070
]Search in Google Scholar
[
12. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014; 371 (4): 326-338.10.1056/NEJMoa1314258
]Search in Google Scholar
[
13. Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebocontrolled, phase 3 study. The Journal of dermatology. 2014; 41 (12): 1039–1046.10.1111/1346-8138.12668
]Search in Google Scholar
[
14. Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015; 75 (3): 329-38.10.1007/s40265-015-0359-0
]Search in Google Scholar
[
15. Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021; 35 (4): 938-947.10.1111/jdv.17002
]Search in Google Scholar
[
16. Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/ pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015; 29(6):1082-1090.10.1111/jdv.12751
]Search in Google Scholar
[
17. Körber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies. Drugs Aging. 2018; 35 (2): 135-144.10.1007/s40266-018-0520-z
]Search in Google Scholar
[
18. Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderateto-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019; 394 (10201): 831-839.10.1016/S0140-6736(19)31773-8
]Search in Google Scholar
[
19. Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. J Am Acad Dermatol. 2019; 80 (5): 1344-1352.10.1016/j.jaad.2019.01.06630716404
]Search in Google Scholar
[
20. Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021; 184 (1): 50-59.10.1111/bjd.19341798395432594522
]Search in Google Scholar
[
21. Wu NL, Hsu CJ, Sun FJ, Tsai TF. Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study. J Dermatol. 2017; 44 (10): 1129-1137.10.1111/1346-8138.13900
]Search in Google Scholar
[
22. Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017; 177 (1): 47-62.10.1111/bjd.15015
]Search in Google Scholar
[
23. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016; 375 (4): 345-356.10.1056/NEJMoa1512711
]Search in Google Scholar
[
24. Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016; 15 (10): 1413-20.10.1080/14740338.2016.1221923
]Search in Google Scholar
[
25. Reich K, Warren RB, Coates LC, Di Comite G. Longterm efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020; 34 (6): 1161-1173.10.1111/jdv.16124
]Search in Google Scholar
[
26. Ling Y, Puel A. IL-17 and infections. Actas Dermosifiliogr. 2014; 105 Suppl 1: 34-40.10.1016/S0001-7310(14)70016-X
]Search in Google Scholar
[
27. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011; 332 (6025): 65-68.10.1126/science.1200439307004221350122
]Search in Google Scholar
[
28. Yiu ZZ, Griffiths CE. Interleukin 17-A inhibition in the treatment of psoriasis. Expert Rev Clin Immunol. 2016; 12 (1): 1-4.10.1586/1744666X.2016.111273926561053
]Search in Google Scholar
[
29. Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther. 2019; 19 (1): 45-54.10.1080/14712598.2019.155523530500317
]Search in Google Scholar
[
30. Eppinga H, Poortinga S, Thio HB, et al. Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017; 23 (10): 1783-1789.10.1097/MIB.000000000000116928617755
]Search in Google Scholar
[
31. Egeberg A, Thyssen JP, Burisch J, Colombel JF. Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study. J Invest Dermatol. 2019; 139 (2): 316-323.10.1016/j.jid.2018.07.029
]Search in Google Scholar
[
32. van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016; 75 (1): 83-98.e4.10.1016/j.jaad.2016.03.024
]Search in Google Scholar
[
33. Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018; 77 (6): 890-897.10.1136/annrheumdis-2017-212687
]Search in Google Scholar
[
34. Fujita H, Ohtsuki M, Morita A, et al. Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan. J Dermatol. 2021; 48 (2): 175-183.10.1111/1346-8138.15655
]Search in Google Scholar
[
35. Roman M, Madkan VK, Chiu MW. Profile of secukinumab in the treatment of psoriasis: current perspectives. Ther Clin Risk Manag. 2015; 11: 1767-77.10.2147/TCRM.S79053
]Search in Google Scholar
[
36. Fieldhouse KA, Ukaibe S, Crowley EL, Khanna R, O’Toole A, Gooderham MJ. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs Context. 2020; 9: 2020-2-1.10.7573/dic.2020-2-1
]Search in Google Scholar
[
37. Ley K, Smith E, Stark MA. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol Res. 2006; 34 (3): 229-42.10.1385/IR:34:3:229
]Search in Google Scholar
[
38. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013; 2 (2): e000062.10.1161/JAHA.113.000062364727823557749
]Search in Google Scholar
[
39. Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017; 176 (4): 890-901.10.1111/bjd.14964541267027518205
]Search in Google Scholar
[
40. Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015; 172 (2): 484-493.10.1111/bjd.1334825132411
]Search in Google Scholar
[
41. Grace E, Goldblum O, Renda L, et al. Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis. Dermatol Ther (Heidelb). 2020; 10 (1): 99-106.10.1007/s13555-019-00341-2699457531734937
]Search in Google Scholar
[
42. Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate-tosevere palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2020; 182 (4): 889-899.10.1111/bjd.1833131286480
]Search in Google Scholar
[
43. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderateto-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013; 168 (2): 412-421.10.1111/bjd.1211023106107
]Search in Google Scholar
[
44. Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Immunol Res. 2019; 2019: 2546161.10.1155/2019/2546161675490431583255
]Search in Google Scholar
[
45. Ortiz-Salvador JM, Saneleuterio-Temporal M, Magdaleno-Tapial J, et al. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J Am Acad Dermatol. 2019; 81 (2): 427-432.10.1016/j.jaad.2019.02.06230872150
]Search in Google Scholar
[
46. Loft ND, Vaengebjerg S, Halling AS, Skov L, Egeberg A. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2020; 34 (6): 1151-1160.10.1111/jdv.1607331721310
]Search in Google Scholar
[
47. Kim HJ, Lebwohl MG. Biologics and Psoriasis:The Beat Goes On. Dermatol Clin. 2019; 37 (1): 29-36.10.1016/j.det.2018.07.00430466686
]Search in Google Scholar
[
48. Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018; 45 (3): 279-286.10.1111/1346-8138.1409629226369
]Search in Google Scholar
[
49. Masson Regnault M, Castañeda-Sanabria J, Diep Tran MHT, et al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2020; 34 (2): 293-300.10.1111/jdv.1587831419355
]Search in Google Scholar
[
50. Wu D, Yue J, Tam LS. Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology (Oxford). 2018; 57 (3): 563-571.10.1093/rheumatology/kex45229244162
]Search in Google Scholar
[
51. Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs. 2017; 31 (4): 299-316.10.1007/s40259-017-0231-8554881428612180
]Search in Google Scholar
[
52. Topaloğlu Demir F, Özkök Akbulut T, Kıvanç Altunay İ, et al. Evaluation of the adverse effects of biological agents used in the treatment of psoriasis: A multicenter retrospective cohort study. Dermatol Ther. 2020; 33(6): e14216.10.1111/dth.1421632827159
]Search in Google Scholar